{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:00:28Z","timestamp":1785837628655,"version":"3.56.0"},"reference-count":81,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.<\/jats:p>","DOI":"10.3390\/cells12222656","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:30:50Z","timestamp":1700440250000},"page":"2656","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-1445","authenticated-orcid":false,"given":"Benedetta","family":"Sonego","sequence":"first","affiliation":[{"name":"Dermatology Clinic, University of Trieste, 35125 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalberto","family":"Ibatici","sequence":"additional","affiliation":[{"name":"UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rivoli","sequence":"additional","affiliation":[{"name":"UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-6080","authenticated-orcid":false,"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[{"name":"UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sola","sequence":"additional","affiliation":[{"name":"Surgical Pathology, Galliera Hospital, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Massone","sequence":"additional","affiliation":[{"name":"Dermatology Unit & Scientific Directorate, Galliera Hospital, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification, and prognostic factors: An EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104126","DOI":"10.1016\/j.lpm.2022.104126","article-title":"Primary cutaneous lymphoma: The 2018 update of the WHO-EORTC classification","volume":"51","author":"Willemze","year":"2022","journal-title":"Presse Med."},{"key":"ref_4","first-page":"413","article-title":"An expert consensus report on mycosis fungoides in Italy: Epidemiological impact and diagnostic-therapeutic pathway","volume":"156","author":"Alaibac","year":"2021","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/01.pas.0000126719.71954.4f","article-title":"Subcutaneous, blastic natural killer (NK), NK\/T-cell, and other cytotoxic lymphomas of the skin: A morphologic, immunophenotypic, and molecular study of 50 patients","volume":"28","author":"Massone","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/PAS.0b013e3181c5e26b","article-title":"Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients","volume":"34","author":"Cota","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1097\/HS9.0000000000000841","article-title":"Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper from an Ad Hoc International Expert Panel","volume":"7","author":"Pagano","year":"2023","journal-title":"Hemasphere"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","article-title":"Blastic plasmacytoid dendritic cell neoplasms: Results of an international survey on 398 adult patients","volume":"4","author":"Laribi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, IARC Press."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00000478-199902000-00001","article-title":"CD4 + CD56 + cutaneous neoplasms: A distinct hematological entity? Groupe Francais d\u2019Etude des Lymphomes Cutanes (GFELC)","volume":"23","author":"Petrella","year":"1999","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_11","first-page":"257","article-title":"Blastic plasmacytoid dendritic cell neoplasm: Emerging developments and special considerations for 2023","volume":"21","author":"Pemmaraju","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104109","DOI":"10.1016\/j.lpm.2022.104109","article-title":"Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management","volume":"51","author":"Fava","year":"2022","journal-title":"Presse Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: Final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jid.2020.07.026","article-title":"Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and\/or S\u00e9zary Syndrome","volume":"141","author":"Quaglino","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hon.2832","article-title":"Critical concepts and management recommendations for cutaneous T-cell lymphoma: A consensus-based position paper from the Italian Group of Cutaneous Lymphoma","volume":"39","author":"Zinzani","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/14740338.2019.1643837","article-title":"A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma","volume":"18","author":"Afifi","year":"2019","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S\u00e9zary Syndrome: A Multicenter Phase II Study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104110","DOI":"10.1016\/j.lpm.2022.104110","article-title":"New biotherapies for the treatment of cutaneous T-cell lymphomas","volume":"51","year":"2022","journal-title":"Presse Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients with Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0959-8049(21)00668-7","article-title":"Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides\/S\u00e9zary syndrome patients relapsed\/refractory after a previous systemic treatment (PARCT)","volume":"156","author":"Stadler","year":"2021","journal-title":"Eur. J. Cancer."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: A single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"Guitera","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: An international, first-inhuman, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cncr.34005","article-title":"Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma","volume":"128","author":"Leupin","year":"2022","journal-title":"Cancer"},{"key":"ref_28","first-page":"98","article-title":"CD123 (interleukin 3 receptor alpha chain)","volume":"15","author":"Moretti","year":"2001","journal-title":"J. Biol. Regul. Homeost. Agents."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.pas.0000153121.57515.c6","article-title":"Histopathologic features of early (patch) lesions of mycosis fungoides: A morphologic study on 745 biopsy specimens from 427 patients","volume":"29","author":"Massone","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cerroni, L. (2020). Skin Lymphoma, The Illustrated Guide, Wiley-Blackwell. [5th ed.].","DOI":"10.1002\/9781119485933"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1365-2133.2008.08761.x","article-title":"The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality","volume":"159","author":"Massone","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/DAD.0000000000000493","article-title":"Phenotypic Variation in Different Lesions of Mycosis Fungoides Biopsied Within a Short Period of Time from the Same Patient","volume":"38","author":"Kash","year":"2016","journal-title":"Am. J. Dermatopathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Alberti-Violetti, S., Sapienza, M.R., Del Corvo, M., Melle, F., Motta, G., Venegoni, L., Cerroni, L., Cota, C., Pileri, A., and Berti, E. (2023). A Microenvironment-Related Nine-Gene Signature May Predict Survival in Mycosis Fungoides Patients at Diagnosis. Cells, 12.","DOI":"10.3390\/cells12151944"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/his.13960","article-title":"C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment","volume":"76","author":"Geller","year":"2020","journal-title":"Histopathology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/DAD.0000000000000207","article-title":"Mycosis fungoides: An updated review of clinicopathologic variants","volume":"36","author":"Ahn","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jdv.17971","article-title":"Paediatric mycosis fungoides\u2014Characteristics, management and outcomes with particular focus on the folliculotropic variant","volume":"36","author":"Reiter","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hon.2850","article-title":"Cutaneous T-cell lymphomas\u2014An update 2021","volume":"39","author":"Kempf","year":"2021","journal-title":"Hematol Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/j.1600-0560.2007.00979.x","article-title":"Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin","volume":"35","author":"Werner","year":"2008","journal-title":"J. Cutan. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjd.19823","article-title":"Most rare subtypes of cutaneous lymphoma display variable CD30 expression: Analysis of the German Cutaneous Lymphoma Network","volume":"185","author":"Wehkamp","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.semdp.2016.11.005","article-title":"A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders","volume":"34","author":"Kempf","year":"2017","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0560.2007.00778.x","article-title":"The morphologic spectrum of primary cutaneous anaplastic large T-cell lymphoma: A histopathologic study on 66 biopsy specimens from 47 patients with report of rare variants","volume":"35","author":"Massone","year":"2008","journal-title":"J. Cutan. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/DAD.0b013e3182a5683a","article-title":"Phenotypic variability in primary cutaneous anaplastic large T-cell lymphoma: A study on 35 patients","volume":"36","author":"Massone","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1159\/000530884","article-title":"Pediatric Primary Cutaneous Lymphoma in China: A Retrospective Study","volume":"239","author":"Zhang","year":"2023","journal-title":"Dermatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cup.14426","article-title":"Lymphomatoid papulosis with DUSP22-IRF4 rearrangement: A case report and literature review","volume":"50","author":"Niu","year":"2023","journal-title":"J. Cutan. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Nowicka, D., Mertowska, P., Mertowski, S., Hymos, A., Forma, A., Michalski, A., Morawska, I., Hrynkiewicz, R., Nied\u017awiedzka-Rystwej, P., and Grywalska, E. (2022). Etiopathogenesis, Diagnosis, and Treatment Strategies for Lymphomatoid Papulosis with Particular Emphasis on the Role of the Immune System. Cells, 11.","DOI":"10.3390\/cells11223697"},{"key":"ref_49","first-page":"355","article-title":"PD-1 and PD-L1 expression in mycosis fungoides and S\u00e9zary Syndrome","volume":"157","author":"Pileri","year":"2022","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bjd.21063","article-title":"Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and S\u00e9zary syndrome: Association with disease stage and clinical outcome","volume":"187","author":"Palmer","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1600-0560.2007.00915.x","article-title":"CD4-negative variant of CD4+\/CD56+ hematodermic neoplasm: Description of three cases","volume":"35","author":"Ascani","year":"2008","journal-title":"J. Cutan. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1111\/ajd.13399","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm: Underlining the importance of an early diagnosis and the use of tagraxofusp therapy before wide dissemination","volume":"62","author":"Massone","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur. J. Cancer."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood.2020008241","article-title":"Integrating novel agents into the treatment of advanced mycosis fungoides and S\u00e9zary syndrome","volume":"141","author":"Khodadoust","year":"2023","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2217\/fon-2017-0263","article-title":"Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: A targeted approach to management","volume":"13","author":"Scarisbrick","year":"2017","journal-title":"Future Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","article-title":"Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and S\u00e9zary Syndrome","volume":"132","author":"Corbin","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/bjd.18806","article-title":"Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides","volume":"182","author":"Battistella","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bogacka, J., Pawlik, K., Ciapa\u0142a, K., Ciechanowska, A., and Mika, J. (2022). CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415638"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/DDDT.S185896","article-title":"Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or S\u00e9zary Syndrome: Efficacy, Safety, and Patient Selection","volume":"14","author":"Blackmon","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jdv.17523","article-title":"Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: A post hoc analysis of the MAVORIC trial","volume":"35","author":"Cowan","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with Sezary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjd.20708","article-title":"Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: A retrospective single-centre case series","volume":"186","author":"Trum","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-021-00624-7","article-title":"Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management","volume":"12","author":"Musiek","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or S\u00e9zary Syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","volume":"139","author":"Darbord","year":"2022","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1111\/jdv.18831","article-title":"Mogamulizumab-associated rashes, their presentation and prognostic significance: A single-centre retrospective case series analysis","volume":"37","author":"Pileri","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jaad.2023.05.082","article-title":"Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides\/S\u00e9zary syndrome; a single-center experience","volume":"89","author":"Jfri","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamadermatol.2018.0884","article-title":"Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis Fungoides and Sezary syndrome","volume":"154","author":"Dai","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_69","unstructured":"(2018). Mogamulizumab [Package Insert], Kyowa Kirin, Inc."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Jouandet, M., Nakouri, I., Nadin, L., Kieny, A., Samimi, M., Adamski, H., Qu\u00e9reux, G., Chaby, G., Dompmartin, A., and L\u2019Orphelin, J.M. (2022). Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study. Cancers, 14.","DOI":"10.3390\/cancers14071659"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.19134","article-title":"Effectiveness of mogamulizumab in patients with Mycosis Fungoides or S\u00e9zary syndrome: A multicentre, retrospective, real-world French study","volume":"37","author":"Quereux","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.2147\/CMAR.S377015","article-title":"Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas","volume":"14","author":"Caruso","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100629","DOI":"10.1016\/j.adro.2020.11.014","article-title":"Low-Dose Total Skin Electron Beam Therapy Combined with Mogamulizumab for Refractory Mycosis Fungoides and S\u00e9zary Syndrome","volume":"6","author":"Fong","year":"2020","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_74","unstructured":"(2023, August 20). Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients with Stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04128072."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","article-title":"Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients with Cutaneous T-cell Lymphoma","volume":"21","author":"Porcu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1080\/10428194.2021.1953007","article-title":"Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial","volume":"62","author":"Horwitz","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamadermatol.2013.10099","article-title":"Alemtuzumab Therapy for Leukemic Cutaneous T-Cell Lymphoma: Diffuse Erythema as a Positive Predictor of Complete Remission","volume":"150","author":"Watanabe","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","article-title":"CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin\u2019s lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin\u2019s Lymphoma","volume":"16","author":"Lundin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000077322","article-title":"Familial cutaneous mycosis fungoides: Successful treatment with a combination of gemcitabine and alemtuzumab","volume":"208","author":"Weder","year":"2004","journal-title":"Dermatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: Clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/22\/2656\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:25:52Z","timestamp":1760131552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/22\/2656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":81,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["cells12222656"],"URL":"https:\/\/doi.org\/10.3390\/cells12222656","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}